ProCE Banner Activity

Therapeutic Planning in NSCLC Harboring Exon 20 Insertion Mutations

Slideset Download
Download this slideset on treatment of NSCLC harboring Exon 20 insertion mutations.

Released: November 22, 2021

Expiration: November 21, 2022

No longer available for credit.

Share

Faculty

Enriqueta Felip

Enriqueta Felip, MD

Head, Thoracic Oncology Unit
Oncology Service
Vall d Hebron University Hospital
Barcelona, Spain

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen Pharmaceutica NV

Faculty Disclosure

Primary Author

Enriqueta Felip, MD

Head, Thoracic Oncology Unit
Oncology Service
Vall d Hebron University Hospital
Barcelona, Spain

Enriqueta Felip, MD, has disclosed that she has received funds for research support from Fundación Merck Salud; consulting fees from AbbVie, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Guardant Health, Janssen, Lilly, Merck KGaA, Novartis, Pfizer, Roche, Samsung, and Takeda; fees for non-CME/CE services from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Takeda; and other financial or material support from Grífolis.